Background: TNF-TNFR2 signaling has been indicated to be involved in CD4+ T lymphocyte differentiation. However, its role in allergic airway inflammation is not well understood. Objectives: The aim of this study was to investigate the role of TNF-TNFR2 signaling in allergic airway inflammation. Methods and Results: In this study, we used an allergen-induced asthma model to show that TNF-TNFR2 signaling alleviated allergic airway inflammation by reducing the airway infiltration of eosinophils and neutrophils. Activated TNF-TNFR2 signaling decreased the expression of Th2 and Th17 cytokines in serum and bronchoalveolar lavage fluid. Furthermore, TNF-TNFR2 signaling inhibited Th2 and Th17 polarization but promoted Th1 and CD4+CD25+ T cell differentiation in vivo. Conclusions: Our study indicates that TNF-TNFR2 signaling alleviates allergic airway inflammation through inhibition of Th2 and Th17 cell differentiation.
Introduction
Allergic asthma is a common chronic airway disease that affects millions of people worldwide [1, 2] . A vast array of cells, such as eosinophils, neutrophils, mast cells, and T lymphocytes, are involved in the airway inflammation of asthma [3] [4] [5] . Th2 cells, as well as their cytokines IL-4, IL-5, and IL-13, have been proven to underlie the process of allergic asthma [6, 7] . Recent studies have shown that the IL-17 secreted by Th17 cells is able to induce neutrophil recruitment [8, 9] . Moreover, overexpression of IL-17 has been found in sputum, bronchoalveolar lavage fluid (BALF), and lung tissue in chronic allergic airway inflammation [10] [11] [12] . Our previous studies showed that Th17, similar to Th2, is also associated with airway inflammation in asthma [13, 14] . Therefore, the effective inhibition of Th2 and Th17 cell differentiation may be important for controlling airway inflammation in asthma.
TNFR2 (tumor necrosis factor receptor 2) is a member of the tumor necrosis factor super family. Compared to TNFR1, TNFR2 is expressed in a more limited manner on certain populations of lymphocytes, and it is involved in the differentiation and survival of lymphocytes [15] . As Chen and Oppenheim [16, 17] reported, TNFR2 promotes the activation, expansion, and survival of Treg DOI: 10.1159/000493583 cells, especially in the inflammatory environment. Furthermore, Candel et al. [18] demonstrated that TNFR2 deficiency may exacerbate oxidative stress-induced inflammation. Another study indicated that lack of TNFR2-aggravated radiation induced inflammation of the nervous system [19] . Our recent study also demonstrated that impaired TNFR2 signaling promotes Th2 and Th17 polarization and exacerbates allergic airway inflammation [20] . However, whether activated TNFR2 signaling can alleviate allergic airway inflammation is unclear.
The current findings demonstrated that activated TNFR2 signaling alleviated airway inflammation by decreasing eosinophil and neutrophil recruitment. Moreover, TNFR2 signaling activation reduced Th2 and Th17 cytokine expression. Furthermore, TNF-TNFR2 signaling inhibited Th2 and Th17 polarization but promoted Th1 and CD4+CD25+ T cell differentiation in vivo. Our results thus indicate a critical role of TNFR2 signaling in allergic airway inflammation through regulation of Th2 and Th17 differentiation.
Materials and Methods
Mice Six-week-old female BALB/c mice were purchased from Shanghai SLAC Co. (Shanghai, China). All animal care and handling protocols were approved by the Ethics Committee of Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine. All of the experiments were carried out in accordance with the Guide for the Care and Use of Laboratory Animals.
Asthma Model and TNFR2 Signaling Intervention
We generated an asthma model according to previously published protocols [13] . Briefly, mice were sensitized intraperitoneally twice on days 0 and 14 with 100 µg of OVA (Sigma-Aldrich, St. Louis, MO, USA) and 1 mg of Al(OH) 3 (Thermo Scientific, Waltham, MA, USA). On days 25, 26, and 27, the mice were challenged with 100 µg of OVA intranasally. For TNFR2 signaling ac- Figure 1 .
Collection of Serum and BALF
Mice were sacrificed by an overdose of 100 mg/kg of pentobarbital intraperitoneally 24 h after the final challenge. Blood was collected by cardiac puncture. After centrifugation at 3,000 rpm for 15 min at 4 ° C, serum was collected and stored at -80 ° C for cytokine analysis. We used 0.8 mL of cold phosphate-buffered saline for BALF, which was collected and centrifuged at 400 g for 5 min at 4 ° C.The supernatant was collected and stored at -80 ° C, while the precipitate was analyzed for cellular composition using WrightGiemsa staining.
Lung Histology
The right lungs were removed and fixed in 4% buffered paraformaldehyde for at least 24 h at room temperature. The paraffin lung sections were stained with hematoxylin and eosin (HE) or periodic acid-Schiff (PAS) and analyzed by microscope under ×200 magnification.
Cytokine Analysis
Lymphocytes derived from the spleen were cultured in vitro and stimulated with OVA (10 μg/mL) for 3 days. Then, the cultured supernatant was collected and stored at -80 ° C for cytokine analysis. IL-4, IL-5, IL-10, IFN-γ, and IL-17A from serum, BALF, and cultured supernatant were analyzed by enzyme-linked immunosorbent assay kits (eBioscience, San Diego, CA, USA) according to the manufacturer's instructions. These results were analyzed by a Bio-Rad Bio-Plex instrument (Bio-Rad, Hercules, CA, USA).
Flow Cytometry
For CD4+ T cell polarization analysis, lymphocytes from spleen and lung-draining mediastinal lymph nodes were separated and stimulated with a leukocyte activation cocktail (BD Bioscience, Franklin Lakes, NJ, USA) at 2 µL/mL for 5 h. CD4-FITC and CD25-PE (eBioscience) were used to label CD4+CD25+ T cells. For intracellular cytokine staining, lymphocytes were permeabilized and fixed with a Cytofix/Cytopermea Kit (eBioscience). IFN-γ-APC, IL-4-PE, and IL-17-PerCP-cy5.5 (eBioscience) were used to label Th1, Th2, and Th17 cells, respectively. All the samples were analyzed by BD FACSCalibur (BD Bioscience).
Real-Time PCR
Total RNA of lymphocytes from spleens was extracted using TRIzol reagent (Takara Biotechnology, Dalian, China), and cDNA was synthesized using a PrimeScript TM RT reagent kit (Takara Biotechnology, Dalian, China). Ask1 and Bmx, which are the downstream genes of TNFR1 and TNFR2, respectively, were examined with an ABI 7500 real-time PCR system using a SYBR Premix Ex Taq TM II kit. The following primer pairs were used: Ask1 forward: 5′-CAAATCAGACAGTCCGACGG-3′; reverse: 5′-GTG-CATTCTGGGAGTCATGG-3′. Bmx forward: 5′-GGAAAGTTC-CTGTGTTGCCA-3′; reverse: 5′-TGGGAGCTCTGTGTTTC TC-A-3′. Actin forward: 5′-GTGCTATGTTGCTCTAGACTTCG-3′; reverse: 5′-ATGCCACAGGATTCCATACC-3′.
Western Blotting
Lymphocytes from spleens were lysed by means of radio-immunoprecipitation assay buffer containing protease and phosphatase inhibitor cocktails (Sigma-Aldrich). Protein samples (50 μg) were run on sodium dodecyl sulfate-polyacrylamide gels and transferred to polyvinylidene difluoride membranes. After incubation with a blocking buffer (5% nonfat milk in 10 mM Tris-HCl, pH 7.5, 100 mM NaCl, 0.1% [w/v] Tween-20) for 2 h, the membrane was incubated with primary antibodies for T-bet, GATA3, FoxP3, RORγ (all 1: 300; Boster, Wuhan, China), or actin (1: 2,000; Beyotime, Shanghai, China) and then visualized with a horseradish peroxidase-conjugated secondary antibody (1: 2,000; Beyotime) and enhanced chemiluminescence agents. The relative quantities of proteins were estimated by scanning densitometry (ChemiDoc XRS Systems, Bio-Rad Laboratories Inc.) and analyzed by Image Lab 5.0 software (Bio-Rad Laboratories Inc.).
Statistical Analysis
Statistical analysis was performed using SPSS 17.0 software. Data are expressed as the mean ± SEM. An independent t test was used for the comparisons between two groups. For multiple comparisons one-way ANOVA was used first and, if a significant difference was detected, an LSD post hoc test was performed between pairs of groups. A p value < 0.05 was considered statistically significant. 
Results

TNFR2 Signaling Is Activated Effectively by TNF-α and TNFR1 Blocking Antibody
To identify whether TNFR2 signaling was activated by TNF-α and TNFR1 blocking antibody, we first examined the Ask1 and Bmx gene expression. As shown in Figure  2 , the expression of the Bmx gene was dramatically increased in the spleen lymphocytes from TNF-α and TNFR1 blocking antibody-treated mice compared with the expression in untreated mice. Additionally, the expression of the Ask1 gene was significantly decreased in the spleen lymphocytes from TNF-α and TNFR1 blocking antibody-treated mice compared with that from untreated mice. These results indicate that TNFR2 signaling was activated effectively by TNF-α and TNFR1 blocking antibody. Furthermore, the expression of both Ask1 and Bmx genes were decreased when TNFR1 and TNFR2 signaling were inhibited simultaneously.
TNF-TNFR2 Signaling Activation Alleviates Airway Inflammation
Our previous study showed that impaired TNFR2 signaling aggravated airway inflammation [20] . To evaluate the effect of TNF-TNFR2 signaling activation on airway inflammation, we first activated TNF-TNFR2 signaling by TNF-α and TNFR1 blocking antibody. As shown in Figure 3a and b, the inflammatory cell infiltration and mucus secretion were greatly inhibited in the lungs from the TNF-TNFR2 activation group compared with the control group. Furthermore, inflammatory cells in the BALF were typed and quantified by Wright-Giemsa staining. As shown in Figure 3c , the eosinophils and neutrophils were both significantly decreased in the TNF-TNFR2 activation group compared with the untreated group. Next, when TNFR1 and TNFR2 signaling were inhibited simultaneously, as shown in Figure 3a -c, the inhibited airway inflammation was restored. Taken together, these findings suggest that TNF-TNFR2 signaling activation alleviates airway inflammation.
TNF-TNFR2 Signaling Activation Inhibits Th2 and Th17 Cytokine Expression
Since Th2 and Th17 cytokines regulate airway inflammation by the recruitment of eosinophils and neutrophils, respectively, we subsequently investigated whether TNF-TNFR2 signaling activation has an impact on type 2 and type 17 cytokine expression. As shown in Figure  4a -d, the expression of IL-4 and IL-5 were significantly reduced in the serum and BALF, as well as in cell culture supernatant from the TNF-TNFR2 signaling activation group compared with the control group. Moreover, the production of IL-17, a Th17 cytokine, was also significantly decreased in the BALF and cell culture supernatant compared with the untreated group. However, IL-10, a typical tolerogenic cytokine [21] , which can inhibit proinflammatory cytokine synthesis, was significantly increased compared with the untreated group. Similarly, when TNFR1 and TNFR2 signaling were inhibited simultaneously, the expression of proinflammatory cytokines IL-4, IL-5, and IL-17 were increased, while the expression of IL-10 was decreased. These results suggest that TNF-TNFR2 signaling activation inhibits proinflammatory cytokine expression. 
TNF-TNFR2 Signaling Activation Influences CD4+ T Lymphocyte Differentiation in vivo
Chen and Oppenheim [16] reported that TNFR2 is essential for the stabilization of CD4+FoxP3+ Tregs in vitro. Our previous study demonstrated that impaired TNF-TNFR2 signaling may also promote Th2 and Th17 polarization [20] . Therefore, we next examined the impact of TNF-TNFR2 signaling activation on CD4+ T lymphocyte differentiation in vivo. As shown in Figure  5a -d, the differentiation of Th1 and CD4+CD25+ T cells from spleen and lung-draining lymph nodes were significantly enhanced in the TNF-TNFR2 signaling activation group compared with the control group. In contrast, Th2 and Th17 cell differentiation were significantly inhibited by TNF-TNFR2 signaling activation (Fig. 5e-h) . Next, when TNFR1 and TNFR2 signaling were inhibited simultaneously, differentiation of Th1 and CD4+CD25+ T cells was inhibited, while differentiation of Th2 and Th17 cells was enhanced. Thus, TNF-TNFR2 signaling can influence CD4+ T lymphocyte differentiation.
TNF-TNFR2 Signaling Activation Affects Transcription Factor Expression
To understand the potential mechanism of the effect of TNF-TNFR2 signaling activation on CD4+ T lym- phocyte differentiation, we next examined the expression of transcription factors, such as T-bet, GATA3, FoxP3, and RORγ. As shown in Figure 6 , TNF-TNFR2 signaling activation promoted FoxP3 and T-bet expression but reduced GATA3 and RORγ expression. Consistently, when TNFR1 and TNFR2 signaling were inhibited simultaneously, we observed opposite results. Taken together, the results indicate that TNF-TNFR2 signaling activation can inhibit differentiation of Th2 and Th17 cells by decreasing GATA3 and RORγ expression.
Discussion
TNF-α is a cytokine with various immune regulatory functions [22] . The role of TNF-α in inflammatory disease remains controversial. Previous studies have shown that TNF-α is a proinflammatory mediator and plays an important role in the process of inflammation [23, 24] . However, other studies have also proved that TNF-α has an anti-inflammatory effect [25, 26] . It has been shown that TNF-α functions by TNFR1 and TNFR2 signaling, respectively. TNFR1 signaling plays a major role in the cytotoxic, proinflammatory, and apoptotic effects, while TNFR2 signaling predominantly mediates lymphocyte activation and proliferation [22] . Recently, TNF-TNFR2 signaling has been proven to be involved in the differentiation of CD4+ T lymphocytes [15, 16] . As reported by Wu et al. [27] , the administration of TNF-α to young adult nonobese diabetic mice every other day for 3 weeks can reduce the incidence of diabetes, which may be attributed to the increased number of CD4+CD25+ T cells in the thymus and spleen. Chen et al. [28] reported that TNF-α administration expands CD4+CD25+ T cells via TNFR2 signaling in vitro. Our previous study has also demonstrated that impaired TNF-TNFR2 signaling exacerbates airway inflammation by promoting Th2 and Th17 polarization. Therefore, we hypothesized that the activated TNF-TNFR2 signaling may alleviate allergic airway inflammation. In the current study, TNFR2 signaling was activated by administrating TNF-α and a TNFR1 blocking antibody simultaneously. Our results demonstrate that TNFR2 signaling activation alleviated airway inflammation and inflammatory cytokine expression by inhibition of Th2 and Th17 cell differentiation.
Asthma is characterized by high mucus secretion and infiltration of airway inflammatory cells, such as eosinophils, neutrophils, lymphocytes, and macrophages. In this study, TNFR2 signaling activation profoundly reduced the mucus production and inflammatory cell infiltration in the airway. These results are consistent with the finding of Maier et al. [29] , showing that the activation of TNFR2 signaling protects oligodendrocyte progenitor cells against oxidative stress. Moreover, oligodendroglial TNFR2 mediates membrane TNF-dependent repair in experimental autoimmune encephalomyelitis [30] . Therefore, these findings suggest that TNFR2 signaling activation alleviates airway inflammation in asthma.
Eosinophilia and neutrophilia are associated with type 2 and type 17 immune responses, which are characterized by the production of Th2 and Th17 cytokines, respectively. As expected, TNFR2 signaling activation dramatically reduced the production of the proinflammatory cytokines IL-4, IL-5, and IL-17, but enhanced the production of the anti-inflammatory cytokine IL-10 in serum, BALF, and splenocyte cultures. These results collectively suggest that the alleviation of airway inflammation by TNFR2 signaling activation may be attributed to an altered cytokine expression. CD4+ T lymphocyte differentiation plays an important role in airway inflammation. Recently, TNFR2 signaling has been confirmed to be involved in CD4+ T lymphocyte differentiation. Here, we found that TNFR2 signaling activation inhibited Th2 and Th17 polarization but promoted Th1 and CD4+CD25+ T cell differentiation. Furthermore, we examined the expression levels of transcription factors of each CD4+ T cell subset to clarify the potential mechanism underlying TNFR2 signaling activation in the regulation of CD4+ T lymphocyte differentiation. We found that TNFR2 signaling activation inhibited GATA3 and RORγ expression but promoted FoxP3 and T-bet expression. Together, these data suggest that TNFR2 signaling regulates CD4+ T cell differentiation through activation of different transcription factors.
In conclusion, TNF-TNFR2 signaling activation alleviated airway inflammation, and a potential mechanism may involve the inhibited polarization of Th2 and Th17. 
